Current pharmacotherapies for obesity: A practical perspective

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and purpose: To review the currently available pharmacotherapies for obesity management with a particular focus on the United States. Methods: Narrative review based on literature searches and the latest prescribing information (up to July 2017). Conclusions: Obesity pharmacotherapies may assist those individuals who have obesity, or overweight with comorbidities, who have failed to maintain weight loss with lifestyle modifications alone (caloric restriction and increased physical activity). Currently approved options in the United States include phentermine for short-term use and five obesity pharmacotherapies that can be used long-term (orlistat, lorcaserin, phentermine–topiramate, naltrexone–bupropion, and liraglutide 3.0 mg). If the use of an obesity pharmacotherapy is indicated, treatment should be selected to provide the most appropriate option for each individual and their circumstances. Variables such as contraindications, individual comorbidities, patient choice, patient readiness to incorporate additional behavioral changes (e.g., alcohol prohibition), and cost should guide choices. Implications for Practice: Each of the obesity pharmacotherapies has advantages and disadvantages that can help guide treatment choice. Those receiving treatment may also have individual preferences based on factors such as administration route, frequency of dosing, and/or safety profile. In addition, some options may be particularly appropriate for patients with common obesity-related complications such as depression or diabetes.

Original languageEnglish (US)
Pages (from-to)S43-S52
JournalJournal of the American Association of Nurse Practitioners
Volume29
DOIs
StatePublished - Oct 1 2017
Externally publishedYes

Fingerprint

Obesity
Drug Therapy
Comorbidity
Phentermine
Caloric Restriction
Life Style
Weight Loss
Therapeutics
Alcohols
Exercise
Depression
Safety
Costs and Cost Analysis

Keywords

  • Nurse practitioners
  • obesity
  • pharmacotherapy
  • weight management

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Current pharmacotherapies for obesity : A practical perspective. / Golden, Angela K.

In: Journal of the American Association of Nurse Practitioners, Vol. 29, 01.10.2017, p. S43-S52.

Research output: Contribution to journalArticle

@article{48575e3a987a4e4880eb123c7f0ce47c,
title = "Current pharmacotherapies for obesity: A practical perspective",
abstract = "Background and purpose: To review the currently available pharmacotherapies for obesity management with a particular focus on the United States. Methods: Narrative review based on literature searches and the latest prescribing information (up to July 2017). Conclusions: Obesity pharmacotherapies may assist those individuals who have obesity, or overweight with comorbidities, who have failed to maintain weight loss with lifestyle modifications alone (caloric restriction and increased physical activity). Currently approved options in the United States include phentermine for short-term use and five obesity pharmacotherapies that can be used long-term (orlistat, lorcaserin, phentermine–topiramate, naltrexone–bupropion, and liraglutide 3.0 mg). If the use of an obesity pharmacotherapy is indicated, treatment should be selected to provide the most appropriate option for each individual and their circumstances. Variables such as contraindications, individual comorbidities, patient choice, patient readiness to incorporate additional behavioral changes (e.g., alcohol prohibition), and cost should guide choices. Implications for Practice: Each of the obesity pharmacotherapies has advantages and disadvantages that can help guide treatment choice. Those receiving treatment may also have individual preferences based on factors such as administration route, frequency of dosing, and/or safety profile. In addition, some options may be particularly appropriate for patients with common obesity-related complications such as depression or diabetes.",
keywords = "Nurse practitioners, obesity, pharmacotherapy, weight management",
author = "Golden, {Angela K}",
year = "2017",
month = "10",
day = "1",
doi = "10.1002/2327-6924.12519",
language = "English (US)",
volume = "29",
pages = "S43--S52",
journal = "Journal of the American Association of Nurse Practitioners",
issn = "2327-6886",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Current pharmacotherapies for obesity

T2 - A practical perspective

AU - Golden, Angela K

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background and purpose: To review the currently available pharmacotherapies for obesity management with a particular focus on the United States. Methods: Narrative review based on literature searches and the latest prescribing information (up to July 2017). Conclusions: Obesity pharmacotherapies may assist those individuals who have obesity, or overweight with comorbidities, who have failed to maintain weight loss with lifestyle modifications alone (caloric restriction and increased physical activity). Currently approved options in the United States include phentermine for short-term use and five obesity pharmacotherapies that can be used long-term (orlistat, lorcaserin, phentermine–topiramate, naltrexone–bupropion, and liraglutide 3.0 mg). If the use of an obesity pharmacotherapy is indicated, treatment should be selected to provide the most appropriate option for each individual and their circumstances. Variables such as contraindications, individual comorbidities, patient choice, patient readiness to incorporate additional behavioral changes (e.g., alcohol prohibition), and cost should guide choices. Implications for Practice: Each of the obesity pharmacotherapies has advantages and disadvantages that can help guide treatment choice. Those receiving treatment may also have individual preferences based on factors such as administration route, frequency of dosing, and/or safety profile. In addition, some options may be particularly appropriate for patients with common obesity-related complications such as depression or diabetes.

AB - Background and purpose: To review the currently available pharmacotherapies for obesity management with a particular focus on the United States. Methods: Narrative review based on literature searches and the latest prescribing information (up to July 2017). Conclusions: Obesity pharmacotherapies may assist those individuals who have obesity, or overweight with comorbidities, who have failed to maintain weight loss with lifestyle modifications alone (caloric restriction and increased physical activity). Currently approved options in the United States include phentermine for short-term use and five obesity pharmacotherapies that can be used long-term (orlistat, lorcaserin, phentermine–topiramate, naltrexone–bupropion, and liraglutide 3.0 mg). If the use of an obesity pharmacotherapy is indicated, treatment should be selected to provide the most appropriate option for each individual and their circumstances. Variables such as contraindications, individual comorbidities, patient choice, patient readiness to incorporate additional behavioral changes (e.g., alcohol prohibition), and cost should guide choices. Implications for Practice: Each of the obesity pharmacotherapies has advantages and disadvantages that can help guide treatment choice. Those receiving treatment may also have individual preferences based on factors such as administration route, frequency of dosing, and/or safety profile. In addition, some options may be particularly appropriate for patients with common obesity-related complications such as depression or diabetes.

KW - Nurse practitioners

KW - obesity

KW - pharmacotherapy

KW - weight management

UR - http://www.scopus.com/inward/record.url?scp=85031012729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031012729&partnerID=8YFLogxK

U2 - 10.1002/2327-6924.12519

DO - 10.1002/2327-6924.12519

M3 - Article

C2 - 29024552

AN - SCOPUS:85031012729

VL - 29

SP - S43-S52

JO - Journal of the American Association of Nurse Practitioners

JF - Journal of the American Association of Nurse Practitioners

SN - 2327-6886

ER -